The Swedish Research Council's role within clinical research

You can apply to the Swedish Research Council for funding for clinical research. We also reinforce clinical research in other ways: we coordinate the healthcare regions, evaluate clinical research, make it easier to use register data for research purposes and provide support to biobanks, networks and other research infrastructures.

Continuous mandates in clinical research

As a public agency, we receive our mandates from the Government. They can be found in our ordinance with directive. Here you can find more information about continuous mandates.

Temporary mandates in clinical research

In addition to our continuous mandates, we may receive temporary mandates from the Government. Here you can find more information about these (both ongoing and concluded mandates are shown).

Statistics and follow-up

The Swedish Research Council, via the Office for ALF, is responsible for collecting and reporting on follow-up statistics on clinical research in the regions and universities covered by the ALF agreement. These statistics shall provide a general overview, contribute to the development and provide background material for future ALF evaluations. In parallel with this, we have also been tasked with ensuring access to statistics relating to clinical studies taking place in Sweden outside the ALF agreement.

The regions’ reporting of ALF payments – our statistics (in Swedish) External link.

Bibliometric statistics for publications in clinical research (in Swedish) External link.

Ethical approval for medical research – statistics (in Swedish) External link.

Statistic on (in Swedish) External link.




  1. Grants within clinical therapy research

    You will receive an automated email from Prisma once the reporting period has started.

  2. Results of needs inventory 2021–2022

    Appendix to the Swedish Research Council’s Guide to Infrastructure 2022 At the Swedish Research Council we have a model of prioritisation of research infrastructure that is based on a two-year cycle. The first step of the cycle is an inventory with ...

  3. Diversity in use broadens the benefits of ESS

    ESS, and MAX IV, are strategically very important for Swedish research and innovation, and for strengthening our role as one of the world's foremost knowledge nations. The facilities will provide Sweden with unique conditions for conducting excellent...